A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD
A Multi-Centre, Multinational, Randomized, Double-Blind, Placebo Controlled, Proof Of Concept Trial To Assess The Effects Of A Subject-Optimized Dose Of UK-369,003 On Exercise Capacity In Subjects With Chronic Obstructive Pulmonary Disease
1 other identifier
interventional
136
5 countries
27
Brief Summary
A randomised, controlled study investigating the effect of UK-369,003 on exercise tolerance in patients with COPD
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started Dec 2004
27 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2004
CompletedFirst Submitted
Initial submission to the registry
September 8, 2005
CompletedFirst Posted
Study publicly available on registry
September 13, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2005
CompletedOctober 13, 2006
October 1, 2006
September 8, 2005
October 12, 2006
Conditions
Outcome Measures
Primary Outcomes (1)
Effect on exercise tolerance
Secondary Outcomes (1)
Effect on lung function and quality of life
Interventions
Eligibility Criteria
You may qualify if:
- GOLD criteria 2 to 4
- pack year history of smoking
You may not qualify if:
- Women of child bearing potential
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (28)
Pfizer Investigational Site
Córdoba, Córdoba Province, CP 5016, Argentina
Pfizer Investigational Site
San Miguel de Tucumán, Pcia de Tucuman, 4000, Argentina
Pfizer Investigational Site
San Miguel de Tucumán, Pcia de Tucuman, Argentina
Pfizer Investigational Site
Rosario, Santa Fé, 2000, Argentina
Pfizer Investigational Site
Buenos Aires, 1272, Argentina
Pfizer Investigational Site
Buenos Aires, 1427, Argentina
Pfizer Investigational Site
Ciudad de Beurnos Aires, C1425DQi, Argentina
Pfizer Investigational Site
Ciudad de Buenos Aires,, (C1425DTG), Argentina
Pfizer Investigational Site
Ciudad de Buenos Aires, C1115AAB, Argentina
Pfizer Investigational Site
Ciudad de Buenos Aires, C1416DRV, Argentina
Pfizer Investigational Site
Provincia de Buenos Aires, (1605), Argentina
Pfizer Investigational Site
Camperdown, New South Wales, 2050, Australia
Pfizer Investigational Site
Darlinghurst, New South Wales, 2010, Australia
Pfizer Investigational Site
Chermside, Queensland, 4032, Australia
Pfizer Investigational Site
Adelaide, South Australia, 5000, Australia
Pfizer Investigational Site
Melbourne, Victoria, 3004, Australia
Pfizer Investigational Site
Perth, Western Australia, 6000, Australia
Pfizer Investigational Site
Giessen, 35392, Germany
Pfizer Investigational Site
Greifestein, 35753, Germany
Pfizer Investigational Site
Kochi, Kerala, 682026, India
Pfizer Investigational Site
Mumbai, Maharashtra, 400016, India
Pfizer Investigational Site
Pune, Maharashtra, 411 019, India
Pfizer Investigational Site
Chennai, Tamil Nadu, 600116, India
Pfizer Investigational Site
Vellore, Tamil Nadu, 632002, India
Pfizer Investigational Site
Papworth Everard, Cambridgeshire, CB3 8RE, United Kingdom
Pfizer Investigational Site
Glasgow, G11 6NT, United Kingdom
Pfizer Investigational Site
Newcastle upon Tyne, NE7 7DN, United Kingdom
Pfizer Investigational Site
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 8, 2005
First Posted
September 13, 2005
Study Start
December 1, 2004
Study Completion
December 1, 2005
Last Updated
October 13, 2006
Record last verified: 2006-10